Citations

Clear

16280 citation(s) found for "Yu, David".

Success of Ablation for Atrial Fibrillation in Isolated Left Ventricular Diastolic Dysfunction
Cha, Yong-Mei , Wokhlu, Anita , Asirvatham, Samuel J. , Shen, Win‐Kuang , Friedman, Paul A. , Munger, Thomas M. , Oh, Jae K. , Monahan, Kristi H. , Haroldson, Janis M., Hodge, David O. , Herges, Regina M., Hammill, Stephen C., Packer, Douglas L. , Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 12, 2011 | Volume: 4 | Issue: 5 | Pages: 724-732

10.1161/circep.110.960690 | PMID 21747059 Get It

Background— The efficacy of radiofrequency ablation for atrial fibrillation (AF) in patients with left ventricular (LV) systolic dysfunction and isolated diastolic dysfunction is uncertain. Methods and Results— A prospective cohort of patients with normal and abnormal LV function underwent ablation for antiarrhythmic drug (AAD)-refractory AF. Three groups were compared: 111 patients with systolic dysfunction, defined as LV ejection fraction (LVEF) ≤40%; 157 patients with isolated diastolic dysfunction but preserved LVEF ≥50%; and 100 patients with normal LV function. The primary end point was AAD-free AF elimination at 1 year after ablation. This end point was achieved in 62% of patients with systolic dysfunction, 75% of those with diastolic dysfunction, and 84% of controls ( P =0.007). AF control on or off AADs was achieved in 76% of patients with systolic dysfunction, 85% of those with diastolic dysfunction, and 89% of controls ( P =0.08). In the systolic dysfunction group, 49% experienced an increase in LVEF by ≥5% after ablation, of which 64% achieved normal LVEF. In the diastolic dysfunction group, 30% of patients demonstrated at least 1 grade improvement in diastolic dysfunction. Multivariable analysis demonstrated an increased relative risk of arrhythmia recurrence of 1.8 (95% CI, 1.1 to 3.1; P =0.02) in systolic dysfunction and 1.7 (1.0 to 2.7; P =0.04) in isolated diastolic dysfunction compared with normal function. Conclusions— Although an ablative approach for AF in patients with systolic or diastolic dysfunction is associated with an increased long-term recurrence risk, there is potential for substantial quality-of-life improvement and LV functional benefit.
Flow Diversion for Intracranial Aneurysms
D’Urso, Pietro Ivo , Lanzino, Giuseppe, Cloft, Harry J. , Kallmes, David F.

Mayo Clinic

Stroke | July 8, 2011 | Volume: 42 | Issue: 8 | Pages: 2363-2368

10.1161/strokeaha.111.620328 | PMID 21737793 Get It

The introduction of flow diverters for treatment of intracranial aneurysms represents a major paradigm shift in the treatment of these lesions. The theoretical hallmark of flow diverters is the treatment of the diseased segment harboring the aneurysm instead of treating the aneurysm itself. Flow diverters are designed to induce disruption of flow near the aneurysm neck while preserving flow into parent vessel and adjacent branches. After flow diversion, intra-aneurysmal thrombosis occurs, followed by shrinkage of the aneurysmal sac as the thrombus organizes and retracts. Preliminary clinical series document effective treatment of wide-neck and/or large and giant aneurysms with acceptable complication rates. However, several questions remain unanswered related to the incidence and mechanisms of aneurysm rupture after treatment with flow diverters, fate of small perforating vessels, and long-term patency rates.
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
Micallef, Ivana N. , Ansell, Stephen M. , Link, Brian K. , Inwards, David J. , Porrata, Luis F. , Johnston, Patrick B. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Allmer, Cristine, Maurer, Matthew J. , Weiner, George J. , Hohl, R.J., Kurtin, Paul J. , Ding, Husheng, Loegering, David A., Schneider, Paula A., Peterson, Kevin, Witzig, Thomas E. , Tang, Hui Jun , Colgan, Joseph P. , Markovic, Svetomir N. , Gupta, Mamta , Habermann, Thomas M. , Kaufmann, Scott H. , Maurer, Matthew , Link, Brian K , Weiner, George

Mayo Clinic

Blood | July 4, 2011 | Volume: 118 | Issue: 18 | Pages: 4882-4889

10.1182/blood-2011-02-334904 | PMID 21725056 Get It

AbstractA phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressive B-cell, indolent B-cell, and T-cell and Hodgkin lymphoma (HL/T) groups, the response rates were 17% (7/42), 7% (1/15), and 31% (11/36), respectively. Of the 19 responders, 7 were diffuse large B-cell non-Hodgkin lymphoma (NHL), 7 T-cell NHL, 1 follicular grade 2, and 4 HL. The median response duration for the 19 responders was 7.2 months (mean, 15.8 months; range, 1.8-62), and 5 patients in the HL/T group are still receiving treatment at 29-64+ months. The grade 3/4 toxicities observed were fatigue and reversible myelosuppression. Correlative studies suggest that Bim and Bcl-2 should be examined as potential predictors of response in future studies. These results indicate that tipifarnib has activity in lymphoma, particularly in heavily pretreated HL/T types, with little activity in follicular NHL. In view of its excellent toxicity profile and novel mechanism of action, further studies in combination with other agents appear warranted. This trial is registered at www.clinicaltrials.gov as #NCT00082888.
Do Chief Resident Scores on the In-Service Examination Predict Their Performance on the American Board of Urology Qualifying Examination?
Kerfoot, B. Price , Baker, Harley, Connelly, Donna, Joseph, David B. , Matson, Sonia, Ritchey, Michael L.

Mayo Clinic

Journal of Urology | June 24, 2011 | Volume: 186 | Issue: 2 | Pages: 634-637

10.1016/j.juro.2011.03.126 | PMID 21683391 Get It

Evaluation of cutaneous allodynia following induction of cortical spreading depression in freely moving rats
Fioravanti, Beatriz, Kasasbeh, Aimen, Edelmayer, Rebecca M. , Skinner, David P., Hartings, Jed A. , Burklund, Ryan D, Felice, Milena De , French, Edward D., Vanderah, Todd W. , Dussor, Gregory O. , Dodick, David W. , Porreca, Frank

Mayo Clinic

Cephalalgia | June 23, 2011 | Volume: 31 | Issue: 10 | Pages: 1090-1100

10.1177/0333102411410609 | PMID 21700643 Get It

Background: Cortical spreading depression (CSD) is a wave of depolarization followed by depression of bioelectrical activity that slowly propagates through the cortex. CSD is believed to be the underlying mechanism of aura in migraine; however, whether CSD can elicit pain associated with migraine headache is unclear. Methods: Awake, freely moving rats were monitored for both CSD events and behavioral responses resulting from dural-cortical pinprick and/or KCl injection to the occipital cortex. Results: We observed tactile allodynia of the face and hindpaws, as well as enhanced Fos expression within the trigeminal nucleus caudalis (TNC) following CSD induced by KCl injection into the cortex, but not by pinprick. Application of KCl onto the dura elicited cutaneous allodynia and increased Fos staining in the TNC but did not elicit CSD events. Conclusions: These data suggest that sustained activation of trigeminal afferents that may be required to establish cutaneous allodynia may not occur following CSD events in normal animals.
Risks of Spontaneous Injury and Extraction of an Active Fixation Pacemaker Lead
Kay, G. Neal , Brinker, Jeffrey, Kawanishi, David T., Love, Charles J. , Lloyd, Margaret A., Reeves, Russell C., PIOGER, G., Fee, JoAnn, Overland, Mary, Ensign, Lisa G., Grunkemeier, Gary L.

Mayo Clinic

Circulation | June 22, 2011 | Volume: 100 | Issue: 23 | Pages: 2344-2352

10.1161/01.cir.100.23.2344 | PMID 10587339 Get It

Background —The Telectronics Accufix pacing leads were recalled in November 1994 after 2 deaths and 2 nonfatal injuries were reported. This multicenter clinical study (MCS) of patients with Accufix leads was designed to determine the rate of spontaneous injury related to the J retention wire and results of lead extraction. Methods and Results —The MCS included 2589 patients with Accufix atrial pacing leads that were implanted at or who were followed up at 12 medical centers. Patients underwent cinefluoroscopic imaging of their lead every 6 months. The risk of J retention wire fracture was ≈5.6%/y at 5 years and 4.7%/y at 10 years after implantation. The annual risk of protrusion was 1.5%. A total of 40 spontaneous injuries were reported to a worldwide registry (WWR) that included data from 34 672 patients (34 892 Accufix leads), including pericardial tamponade (n=19), pericardial effusion (n=5), atrial perforation (n=3), J retention wire embolization (n=4), and death (n=6). The risk of injury was 0.02%/y (95% CI, 0.0025 to 0.072) in the MCS and 0.048%/y (95% CI, 0.035 to 0.067) in the WWR. A total of 5299 leads (13%) have been extracted worldwide. After recall in the WWR, fatal extraction complications occurred in 0.4% of intravascular procedures (16 of 4023), with life-threatening complications in 0.5% (n=21). Extraction complications increased with implant duration, female sex, and J retention wire protrusion. Conclusions —Accufix pacing leads pose a low, ongoing risk of injury. Extraction is associated with substantially higher risks, and a conservative management approach is indicated for most patients.
Pediatric Surgery and Parental Smoking Behavior
Shi, Yu , Warner, David O.

Mayo Clinic

Anesthesiology | June 22, 2011 | Volume: 115 | Issue: 1 | Pages: 12-17

10.1097/aln.0b013e3182207bde | PMID 21694508 Get It

Background Secondhand smoke exposure poses health risks to children, including increased risks for anesthesia. In adult smokers, surgery serves as a teachable moment to motivate quitting. For parents who smoke, having a child undergo surgery may also serve as a teachable moment for smoking behavioral change. This study determined if there is an association between children undergoing a surgical procedure and changes in their parents' smoking behavior. Methods Secondary analyses were performed using logistic regression analysis of 2005 survey data from the National Health Interview Survey. Analyses included 9,289 parent respondents who provided information on both themselves and their children. Results Of the sampled children, 1,112 (12.6%, 95% CI:11.7, 13.4) lived in a home with at least one person who smoked inside in a usual week. In multivariate analysis of the relationship between parent and child surgical history in the past 12 months and smoking behavior, surgery in either the parent (odds ratio 2.19, 95% CI: 1.55, 3.08) or child (odds ratio 2.61, 95% CI: 1.56, 4.35) was associated with an increased likelihood of a quit attempt by the parent. However, these attempts were more likely to be successful if the parents (odds ratio 2.35, 95% CI: 1.35, 4.07), not their child (odds ratio 0.51, 95% CI: 0.20, 1.28), had surgery within the past 12 months. Conclusions Parents who smoke were more likely to make a quit attempt within the past 12 months if their children had surgery within this time, but they were not more likely to succeed in maintaining abstinence and thus could benefit from assistance.
Derivation and Diagnostic Accuracy of the Surgical Lung Injury Prediction Model
Kor, Daryl J. , Alsara, Anas, Pérez, Evans R. Fernández , Malinchoc, Michael, Kashyap, Rahul , Li, Guangxi , Warner, David O. , Gajic, Ognjen , Kashyap, Rahul , Li, Guangxi

Mayo Clinic

Anesthesiology | June 22, 2011 | Volume: 115 | Issue: 1 | Pages: 117-128

10.1097/aln.0b013e31821b5839 | PMID 21694510 Get It

Background Acute lung injury (ALI) is a serious postoperative complication with limited treatment options. A preoperative risk-prediction model would assist clinicians and scientists interested in ALI. The objective of this investigation was to develop a surgical lung injury prediction (SLIP) model to predict risk of postoperative ALI based on readily available preoperative risk factors. Methods Secondary analysis of a prospective cohort investigation including adult patients undergoing high-risk surgery. Preoperative risk factors for postoperative ALI were identified and evaluated for inclusion in the SLIP model. Multivariate logistic regression was used to develop the model. Model performance was assessed with the area under the receiver operating characteristic curve and the Hosmer-Lemeshow goodness-of-fit test. Results Out of 4,366 patients, 113 (2.6%) developed early postoperative ALI. Predictors of postoperative ALI in multivariate analysis that were maintained in the final SLIP model included high-risk cardiac, vascular, or thoracic surgery, diabetes mellitus, chronic obstructive pulmonary disease, gastroesophageal reflux disease, and alcohol abuse. The SLIP score distinguished patients who developed early postoperative ALI from those who did not with an area under the receiver operating characteristic curve (95% CI) of 0.82 (0.78-0.86). The model was well calibrated (Hosmer-Lemeshow, P = 0.55). Internal validation using 10-fold cross-validation noted minimal loss of diagnostic accuracy with a mean ± SD area under the receiver operating characteristic curve of 0.79 ± 0.08. Conclusions Using readily available preoperative risk factors, we developed the SLIP scoring system to predict risk of early postoperative ALI.
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
Lara, Jonathan F. , Thor, Ann D. , Dressler, Lynn G., Broadwater, Gloria , Bleiweiss, Ira J. , Edgerton, Susan M., Cowan, David P., Goldstein, Lori J. , Martino, Silvana, Henderson, I. Craig, Norton, Larry , Hudis, Clifford A. , Berry, Donald A. , Hayes, Daniel F. , B, for the Cancer and Leukemia Group, Ingle, James N. , Winer, Eric P. , Ellis, Matthew J. , B, for the Cancer and Leukemia Group, Norton, Larry

Mayo Clinic

Clinical Cancer Research | June 21, 2011 | Volume: 17 | Issue: 15 | Pages: 5170-5178

10.1158/1078-0432.ccr-11-0484 | PMID 21693655 Get It

Abstract Purpose: p53 as a prognostic and predictive factor in early-stage breast cancer has had mixed results. We studied p53 protein expression, by immunohistochemistry, in a randomized clinical trial of stage II patients treated with adjuvant doxorubicin and cyclophosphamide with or without paclitaxel [Cancer and Leukemia Group B (CALGB) 9344, INT0148]. Patients and Methods: Epithelial p53 expression was evaluated using two immunohistochemical antibodies (DO7 and 1801) in formalin-fixed, paraffin-embedded tissue from patients with node-positive breast cancer who were randomized to four cycles of cyclophosphamide and one of three doses of doxorubicin (60, 75, or 90 mg/m2; AC) and to receive four subsequent cycles of paclitaxel (T) or not. Prognostic and predictive value of p53 protein expression was assessed, independent of treatment assignment, for escalating doses of doxorubicin or addition of T with endpoints of relapse-free (RFS) and overall survival (OS). Results: Of 3,121 patients, 1,887 patient specimens treated on C9344 were obtained, passed quality control, and evaluated for p53 expression. Expression was 23% and 27% for mAbs 1801 and D07, respectively, with 92% concordance. In univariate analysis, p53 positivity was associated with worse OS with either antibody, but only p53 staining with monoclonal antibody 1801 had significantly worse RFS. In multivariate analysis, p53 was not predictive of RFS or OS from either doxorubicin dose escalation or addition of paclitaxel regardless of the antibody. Conclusion: Nuclear staining of p53 by immunohistochemistry is associated with worse prognosis in node-positive patients treated with adjuvant doxorubicin-based chemotherapy but is not a useful predictor of benefit from doxorubicin dose escalation or the addition of paclitaxel. Clin Cancer Res; 17(15); 5170–8. ©2011 AACR.
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
Kumar, Shaji , Zhang, Mei-Jie , Li, Peigang , Dispenzieri, Angela , Krishnan, Amrita , Wirk, Baldeep , Weiss, Brendan M. , Freytes, César O. , Vogl, Dan T. , Vesole, David H. , Meehan, Kenneth R., Hamadani, Mehdi , Lill, Michael, Majhail, Navneet S. , Wiernik, Peter H. , Nath, Rajneesh , Kamble, Rammurti T., Vij, Ravi , Kyle, Robert A. , Hari, Parameswaran , Milone, Giuseppe , Lonial, Sagar , Maiolino, Ângelo , Lazarus, Hillard M. , Callander, Natalie S. , Gale, Robert Peter , Dispenzieri, Angela , Hamadani, Mehdi , Majhail, Navneet S , Hari, Parameswaran

Mayo Clinic

Blood | June 21, 2011 | Volume: 118 | Issue: 7 | Pages: 1979-1988

10.1182/blood-2011-02-337329 | PMID 21690560 Get It

Abstract Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic cell transplantation for multiple myeloma in 1207 recipients in 3 cohorts based on the year of transplantation: 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 488). The most recent cohort was significantly older (53% > 50 years) and had more recipients after prior autotransplantation. Use of unrelated donors, reduced-intensity conditioning and the blood cell grafts increased over time. Rates of acute graft-versus-host (GVHD) were similar, but chronic GVHD rates were highest in the most recent cohort. Overall survival (OS) at 1-year increased over time, reflecting a decrease in treatment-related mortality, but 5-year relapse rates increased from 39% (95% confidence interval [CI], 33%-44%) in 1989-1994 to 58% (95% CI, 51%-64%; P < .001) in the 2001-2005 cohort. Projected 5-year progression-free survival and OS are 14% (95% CI, 9%-20%) and 29% (95% CI, 23%-35%), respectively, in the latest cohort. Increasing age, longer interval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivariate analysis. Survival at 5 years for subjects with none, 1, 2, or 3 of these risk factors were 41% (range, 36%-47%), 32% (range, 27%-37%), 25% (range, 19%-31%), and 3% (range, 0%-11%), respectively (P < .0001).